Related Experiment Video
Updated: Jan 30, 2026

Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques
Published on: June 11, 2019
Cytosorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of Bleeding
Kambiz Hassan1, Jochen Kannmacher2, Peter Wohlmuth3
1Department of Cardiac Surgery, Asklepios Klinik St. Georg, Hamburg, Germany.
Insights
Cytosorb adsorption effectively reduced bleeding complications in high-risk cardiac surgery patients on ticagrelor or rivaroxaban. This safe strategy minimized reoperations and transfusions, improving patient outcomes.
Area of Science:
- Cardiovascular Surgery
- Anesthesiology
- Hematology
Background:
- Patients undergoing emergency open heart surgery often receive coagulation-active substances like ticagrelor or rivaroxaban, increasing bleeding risk.
- Managing bleeding complications in these high-risk patients is a critical challenge in cardiac surgery.
Purpose of the Study:
- To analyze the efficacy and safety of Cytosorb (CytoSorbents) adsorption in reducing bleeding during emergency open heart operations.
- To evaluate the impact of Cytosorb adsorption on patients treated with ticagrelor or rivaroxaban.
Main Methods:
- A study of 55 consecutive patients undergoing emergency cardiac surgery between June 2016 and June 2018.
- Cytosorb adsorption was implemented in the heart-lung machine for 39 patients, while 16 served as a control group without adsorption.
- Bleeding complications, transfusion requirements, and post-operative outcomes were compared between the two groups.
Main Results:
- Patients with Cytosorb adsorption experienced no rethoracotomies and significantly lower 24-hour drainage volumes (350-390 mL) compared to the non-adsorption group.
- The majority of patients in the Cytosorb group did not require blood product transfusions.
- The non-adsorption group showed significantly higher rates of bleeding complications, rethoracotomies, longer operation times, increased drainage, more transfusions, and prolonged ICU and hospital stays.
Conclusions:
- Intraoperative Cytosorb adsorption is a safe and effective method for managing bleeding in patients on ticagrelor or rivaroxaban undergoing emergency cardiac surgery.
- The study recommends Cytosorb adsorption to enhance safety and reduce complications in this patient population.
- This represents the first report on the intraoperative use of Cytosorb adsorption for these specific anticoagulant therapies in emergency cardiac operations.
Background:
The purpose of this study was to analyze the results of Cytosorb (CytoSorbents, Monmouth Junction, NJ) adsorption during emergency open heart operations in patients at high risk of bleeding due to treatment with coagulation-active substances.
Methods:
We investigated 55 consecutive patients (median age 70 years; interquartile range: 60 to 77) who underwent emergency cardiac surgery at our institution between June 2016 and June 2018. All patients were receiving therapy with either ticagrelor (n = 43) or rivaroxaban (n = 12). In 39 of 55 cases, we routinely installed standardized Cytosorb adsorption into the heart-lung machine. Bleeding complications during and after surgery were analyzed in detail and compared with 16 patients without adsorption.
Results:
In the Cytosorb adsorption group, no rethoracotomies had to be performed. Drainage volumes in 24 hours were only 350 mL (interquartile range: 300 to 450 mL) after ticagrelor administration and 390 mL (interquartile range: 310 to 430 mL) after rivaroxaban therapy. In the majority of patients, transfusions of blood products were not needed. Compared with that group, among the group of patients without adsorption, multiple bleeding complications occurred. These were associated with longer total operation (p = 0.0042), higher drainage volumes (p = 0.0037), more transfusions of red blood cells (p = 0.0119) and platelets (p = 0.0475), a significantly higher rethoracotomy rate (p = 0.0003), significantly prolonged stay in the intensive care unit (p = 0.0141), and a longer hospital stay (p = 0.0244).
Conclusions:
The intraoperative use of Cytosorb adsorption of ticagrelor and rivaroxaban in emergency open heart operations is reported for the first time. The data show that the strategy is safe and is an effective method to reduce bleeding complications. We recommend the use for safety in patients with ticagrelor or rivaroxaban undergoing emergency cardiac surgery.
Related Concept Videos
Introduction Cardiac Emergencies
Emerging Adulthood
Bleeding in Fresh Concrete
Bleeding can cause several issues in the concrete structure. Sometimes, the rising water gets trapped beneath large aggregate...
Analyte Adsorption and Distribution
Relative Risk
Operational Amplifiers

